Current Price | $23.86 | Mkt Cap | $7.2B |
---|---|---|---|
Open | $23.78 | P/E Ratio | 36.87 |
Prev. Close | $23.86 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $23.66 - $23.90 | Volume | 1,615,533 |
52-Wk Range | $18.08 - $24.34 | Avg. Daily Vol. | 2,322,293 |
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
Current Price | $23.86 | Mkt Cap | $7.2B |
---|---|---|---|
Open | $23.78 | P/E Ratio | 36.87 |
Prev. Close | $23.86 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $23.66 - $23.90 | Volume | 1,615,533 |
52-Wk Range | $18.08 - $24.34 | Avg. Daily Vol. | 2,322,293 |
The best Bull and Bear pitches based on recency and number of recommendations.
Strong revenue growth and a oncology portfolio that is growing.
This sector is a scary one! Fear, though, is a fools game. I don't expect this stock to move upwards in the very near future. The cash burn is, well, similar to that Texas A&M bonfire tradition.
Read the most recent pitches from players about EXEL.
Recs
Strong revenue growth and a oncology portfolio that is growing.
Recs
From Fidelity or Zacks November 2021:
Revenue Growth (Last 5 Years) = 92.7%
Revenue % Change (Last Qrtr VS. Same Qrtr Prior Year) = 42.1%
Price/Sales (TTM) = 5.2
Recs
First one i picked all by myself, reason:
1. Mkt Cap 7.39B plenty place to grow
2. EPS nxt Yr 94.84%
3.EPS nxt 5Yr 46.00%
4. Sales past 5Yr 107.60%
5. Dept/ Equity 0
Issues:
1. High insider transactions almost 30%
2. Company works on cure for cancer - high volatility
3. EPS this Y -53.80% but justified by Covid-19
Practice and enjoy!
Find the members with the highest scoring picks in EXEL.
beave35 (95.25) Score: +1,583.71
The Score Leader is the player with the highest score across all their picks in EXEL.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
Playa14 | < 20 |
|
5Y | $1.27 | +1,778.74% | +151.15% | +1,627.59 | 0 Comment | ||
beave35 | 95.25 | 12/23/2014 | 5Y | $1.30 | +1,735.24% | +151.54% | +1,583.71 | 0 Comment | ||
tomkao | < 20 | 12/15/2014 | 5Y | $1.40 | +1,604.29% | +159.53% | +1,444.75 | 0 Comment | ||
jack0071 | 63.23 | 12/3/2014 | 5Y | $1.43 | +1,568.53% | +152.37% | +1,416.16 | 0 Comment | ||
portefeuille | 97.15 |
|
NS | $1.44 | +1,556.94% | +159.02% | +1,397.92 | 0 Comment | ||
akoniec | < 20 | 10/9/2014 | 3Y | $1.55 | +1,439.35% | +166.47% | +1,272.88 | 0 Comment | ||
dcoyne13 | 52.34 | 9/16/2014 | 5Y | $1.62 | +1,372.75% | +161.72% | +1,211.03 | 0 Comment | ||
foolerhoff | 84.00 | 1/6/2015 | 5Y | $1.64 | +1,354.88% | +158.88% | +1,196.00 | 0 Comment | ||
garisonmp3z | < 20 | 1/5/2015 | 5Y | $1.67 | +1,328.74% | +156.24% | +1,172.50 | 0 Comment | ||
new2fool23 | 37.31 | 1/5/2015 | 1Y | $1.67 | +1,328.74% | +156.24% | +1,172.50 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.